Specialist commentators

Specialist commentators

The following clinicians contributed to this briefing:

  • Prof Rob Stein, consultant, University College London Hospitals NHS Foundation Trust; chief investigator of the OPTIMA trial, which seeks to investigate the ability of tumour gene expression tests to predict chemotherapy sensitivity for ER-positive HER2-negative breast cancer. There are no plans to assess the MammaTyper technology in the main OPTIMA study. However, with the collaboration of the vendor it was one of 6┬árelated technologies evaluated in the OPTIMA feasibility study. That data is published in the formal report of OPTIMA-prelim and in Bartlett et al. 2016, which is referenced in the briefing document.

  • Dr Roger Hunt, consultant histopathologist, Manchester University NHS Foundation Trust.

  • Mr Simon Pain, consultant breast surgeon, Norfolk and Norwich University Hospitals NHS Trust, sat on advisory boards organised by Genomic Health to discuss use of the Oncotype DX test; gave talks to healthcare professionals about this test. He received honoraria for this work.